DENVER, March 20 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced it will be exhibiting its AspirinWorks(R) Test at the American College of Cardiology (ACC) 57th Annual Scientific Session Exposition. The annual meeting takes place March 29-April 1, 2008, at the McCormick Place Convention Center in Chicago, Ill.
Corgenix representatives will be on-hand during ACC 2008 at booth 4106 to answer questions about the AspirinWorks Test, including availability of the test, the latest supporting clinical data and ordering information.
AspirinWorks is a simple urine test that determines the effect of aspirin on platelets by measuring the level of thromboxane production (aspirin's target). The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's therapy.
Unlike other platelet tests, which require freshly drawn blood that must be evaluated within four hours, the AspirinWorks Test only requires a urine sample that can be obtained in any doctor's office or patient service center, making the test easy for both physician and patient.
"ACC 2008 represents one of the most prestigious gatherings of cardiovascular professionals in the nation and an opportunity for us to further educate the medical community about the AspirinWorks test," said Corgenix' Clinical Affairs Director Gordon Ens. "We're looking forward to demonstrating the value of more clearly understanding a patient's individual response to aspirin."
The AspirinWorks Test, which was launched in the United States in June 2007 following FDA 510(k) clearance, is now available nationwide through major medical reference laboratories, as well as direct to consumers through HealthCheckUSA (http://www.HealthCheckUSA.com).
The AspirinWorks Test Kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11 Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion. The test targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals who take aspirin regularly.
It is important that individuals taking aspirin to lower the risk of a heart attack or stroke consult a physician to determine what dose, frequency and type of aspirin is appropriate for them to achieve the most benefit with the fewest side effects.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at http://www.corgenix.com.
Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
|SOURCE Corgenix Medical Corporation|
Copyright©2008 PR Newswire.
All rights reserved